Delivery Order SPE2DB22D3016-SPE2DB25FBHN8
- Not listed
- The Defense Logistics Agency awarded a $40,532.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C 20 gram/200 milliliter vials, with an ultimate completion date of August 22, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of GAMUNEX-C 20 gram/200 milliliter vials valued at $11,651.54 under a firm fixed-price contract with an ultimate completion date of August 18, 2025. This non-set-aside award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a $23,272.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C (40 gram/400 ml vial), with an ultimate completion date of August 13, 2025. This is an unset-aside, competitively awarded contract that will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. As a child order under a larger contract vehicle, this delivery order represents a single transaction within AmerisourceBergen's extensive pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for GAMUNEX-C 20 gram/200 milliliter vials valued at $11,801.40 with firm fixed pricing. This is a non-set-aside delivery order with an ultimate completion date of September 3, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, is executing this...
- The Defense Logistics Agency awarded a $27,926.40 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of GAMUNEX-C 40 gram/400 mL vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 28, 2025, and performance to be completed at the awardee's Conshohocken, Pennsylvania location. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a $28,323.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C 20 gram/200 milliliter vials with an ultimate completion date of August 22, 2025. This non-set-aside competitive award was issued on August 1, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a $23,602.80 delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C 20 gram/200 mL vials on September 4, 2025, with completion targeted for September 25, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside procurement issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of GAMUNEX-C 20 gram/200 milliliter vials valued at $11,801.40 with a firm fixed price. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract involves no set-aside designation and was competitively...
- The U.S. Department of Defense Medical Supply Chain awarded a firm fixed-price delivery order valued at $13,963.20 to AmerisourceBergen Drug Corp for GAMUNEX-C 40 gram (1 unit) on September 3, 2025, with completion scheduled for September 24, 2025. This non-set-aside award was made competitively and represents a single delivery order under the company's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, valued at $999.99 million through...
- The Defense Logistics Agency awarded a delivery order valued at $7,325.64 to AmerisourceBergen Drug Corp for GAMUNEX-C, a 10 gram/100 mL immunoglobulin vial product, with an ultimate completion date of August 21, 2025. This competitive award, issued on July 31, 2025, utilizes a firm fixed price contract type with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is a...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBHN8Delivery Order
The Defense Logistics Agency awarded a $18,617.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for GAMUNEX-C 40 gram/400 mL vials on September 8, 2025, with completion scheduled for September 29, 2025. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was competitively awarded without set-aside designation to the pharmaceutical distributor's Corporate Office location in Conshohocken, Pennsylvania, where the products are to be performed. AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement through its prime IDC vehicle, which provides comprehensive global pharmaceutical support to military healthcare programs and federal agencies including the Defense Health Agency and U.S. Coast Guard. The company's extensive portfolio of federal contract awards demonstrates its capability to supply specialty medications, brand-name and generic drugs, vaccines, and specialized medical commodities across multiple therapeutic domains. This specific delivery order for GAMUNEX-C immunoglobulin infusion supports the Department of Defense's medical supply chain requirements through DLA's established pharmaceutical procurement framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.6k | 9/8/25 |